Total trials
155
Active
22
Phase 3
4
Total enrollment
240,106
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy | — | — | — | — | — | 1 | |
| Observational | — | — | — | — | — | 1 |
Next readouts
- 2026-12-31
- 2026-12-31
Top conditions
- Hypercholesterolemia11
- Low Back Pain6
- Obesity4
- Atherosclerosis4
- Chronic Myeloid Leukemia4
- Periapical Diseases3
- Neck Pain3
- Acute Coronary Syndrome3
Frequently asked questions about University of Bologna
- How many clinical trials does University of Bologna have on ClinicalTrials.gov?
- University of Bologna is listed as the lead sponsor on 155 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Bologna's trials are in Phase 3?
- 4 of University of Bologna's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Bologna focus on?
- University of Bologna's most-studied conditions on ClinicalTrials.gov are Hypercholesterolemia, Low Back Pain, Obesity, Atherosclerosis, Chronic Myeloid Leukemia.
- When are University of Bologna's next clinical trial readouts?
- University of Bologna has 2 upcoming primary-completion readouts tracked here; the soonest is “Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry”, expected around 2026-12-31.